Clinical trial
Combination Chemotherapy With or Without Rituximab in Non-Hodgkin's Lymphoma
NCT00064116 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00064116 |
|---|---|
| Title | Combination Chemotherapy With or Without Rituximab in Non-Hodgkin's Lymphoma |
| Official title | Randomized Intergroup Trial of First Line Treatment for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma With a CHOP-Like Chemotherapy Regimen With or Without the Anti-CD20 Antibody Rituximab |
| Acronym | IDEC-C2B8 |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | rituximab, CHOP regimen |
| Enrollment | 824 |
| Start date | May 8, 2001 |
| Primary completion | Dec 1, 2010 |
| Completion | Jan 16, 2014 |
| First posted | Jul 9, 2003 |
| Last update posted | Apr 1, 2020 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: